SCHEMBL205653

SCHEMBL205653

CN(Cc1ccccc1)C(=O)CCC(=O)NC1CCC(Cc2cccc(Cl)c2)(N(C)C)CC1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 5/20 0.48
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
EPHX2 P34913 1/20 0.45
THRB P10828 1/20 0.45
HPGD P15428 1/20 0.45
KMT2A Q03164 4/20 0.44
MEN1 O00255 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HTT P42858 1/20 0.44
OPRM1 P35372 2/20 0.42
OPRL1 P41146 2/20 0.42
GAA P10253 1/20 0.40
RIPK1 Q13546 1/20 0.40
AOC3 Q16853 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL207303 0.90 SIGMAR1 (0.46) SIGMAR1EPHX2THRBHPGDKMT2A
SCHEMBL206157 0.90 NPC1 (0.46) NPC1RAB9AKMT2AMEN1HTT
SCHEMBL207425 0.89 GRM5 (0.44) SIGMAR1NPC1EPHX2THRBHPGD
SCHEMBL206862 0.89 EPHX2 (0.43) SIGMAR1NPC1EPHX2THRBHPGD
SCHEMBL206966 0.86 EPHX2 (0.62) SIGMAR1NPC1RAB9AEPHX2THRB
SCHEMBL207263 0.85 LIMK1 (0.42) SIGMAR1RAB9AEPHX2THRBHPGD
SCHEMBL206084 0.85 EPHX2 (0.47) SIGMAR1NPC1EPHX2THRBHPGD
SCHEMBL208454 0.85 ALDH1A1 (0.53) SIGMAR1NPC1RAB9AEPHX2THRB
SCHEMBL205753 0.84 SIGMAR1 (0.45) SIGMAR1EPHX2THRBHPGDKDM4E
SCHEMBL207910 0.83 OPRM1 (0.50) SIGMAR1EPHX2THRBHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD SIGMAR1 3262/4885NPC1 46/4885RAB9A 587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.